Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Dec 1;100(11):2697–2713. doi: 10.1172/JCI119815

Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice.

D E Clouthier 1, S A Comerford 1, R E Hammer 1
PMCID: PMC508473  PMID: 9389733

Abstract

Transgenic mice overexpressing a constitutively active human TGF-beta1 under control of the rat phosphoenolpyruvate carboxykinase regulatory sequences developed fibrosis of the liver, kidney, and adipose tissue, and exhibited a severe reduction in body fat. Expression of the transgene in hepatocytes resulted in increased collagen deposition, altered lobular organization, increased hepatocyte turnover, and in extreme cases, hemorrhage and thrombosis. Renal expression of the transgene was localized to the proximal tubule epithelium, and was associated with tubulointerstitial fibrosis, characterized by excessive collagen deposition and increased fibronectin and plasminogen activator inhibitor-1 immunoreactivity. Pronounced glomerulosclerosis was evident, and hydronephrosis developed with low penetrance. Expression of TGF-beta1 in white and brown adipose tissue resulted in a lipodystrophy-like syndrome. All white fat depots and brown fat pads were severely reduced in size, and exhibited prominent fibroplasia. This reduction in WAT was due to impaired adipose accretion. Introduction of the transgene into the ob/ob background suppressed the obesity characteristic of this mutation; however, transgenic mutant mice developed severe hepato- and splenomegaly. These studies strengthen the link between TGF-beta1 expression and fibrotic disease, and demonstrate the potency of TGF-beta1 in modulating mesenchymal cell differentiation in vivo.

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi M., Suematsu S., Kondo T., Ogasawara J., Tanaka T., Yoshida N., Nagata S. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet. 1995 Nov;11(3):294–300. doi: 10.1038/ng1195-294. [DOI] [PubMed] [Google Scholar]
  2. Ailhaud G., Grimaldi P., Négrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr. 1992;12:207–233. doi: 10.1146/annurev.nu.12.070192.001231. [DOI] [PubMed] [Google Scholar]
  3. Akagi Y., Isaka Y., Arai M., Kaneko T., Takenaka M., Moriyama T., Kaneda Y., Ando A., Orita Y., Kamada T. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 1996 Jul;50(1):148–155. doi: 10.1038/ki.1996.297. [DOI] [PubMed] [Google Scholar]
  4. Antonipillai I., Le T. H., Soceneantu L., Horton R. Transforming growth factor-beta is a renin secretagogue at picomolar concentrations. Am J Physiol. 1993 Oct;265(4 Pt 2):F537–F541. doi: 10.1152/ajprenal.1993.265.4.F537. [DOI] [PubMed] [Google Scholar]
  5. Bartels H., Herbort H., Jungermann K. Predominant periportal expression of the phosphoenolpyruvate carboxykinase and tyrosine aminotransferase genes in rat liver. Dynamics during the daily feeding rhythm and starvation-refeeding cycle demonstrated by in situ hybridization. Histochemistry. 1990;94(6):637–644. doi: 10.1007/BF00271991. [DOI] [PubMed] [Google Scholar]
  6. Bellamy C. O., Malcomson R. D., Harrison D. J., Wyllie A. H. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol. 1995 Feb;6(1):3–16. doi: 10.1006/scbi.1995.0002. [DOI] [PubMed] [Google Scholar]
  7. Border W. A., Noble N. A. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994 Nov 10;331(19):1286–1292. doi: 10.1056/NEJM199411103311907. [DOI] [PubMed] [Google Scholar]
  8. Border W. A., Noble N. A. Transforming growth factor-beta in glomerular injury. Exp Nephrol. 1994 Jan-Feb;2(1):13–17. [PubMed] [Google Scholar]
  9. Border W. A., Noble N. A., Yamamoto T., Harper J. R., Yamaguchi Y. u., Pierschbacher M. D., Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992 Nov 26;360(6402):361–364. doi: 10.1038/360361a0. [DOI] [PubMed] [Google Scholar]
  10. Border W. A., Okuda S., Languino L. R., Sporn M. B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990 Jul 26;346(6282):371–374. doi: 10.1038/346371a0. [DOI] [PubMed] [Google Scholar]
  11. Border W. A., Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest. 1992 Jul;90(1):1–7. doi: 10.1172/JCI115821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bortell R., Owen T. A., Ignotz R., Stein G. S., Stein J. L. TGF beta 1 prevents the down-regulation of type I procollagen, fibronectin, and TGF beta 1 gene expression associated with 3T3-L1 pre-adipocyte differentiation. J Cell Biochem. 1994 Feb;54(2):256–263. doi: 10.1002/jcb.240540214. [DOI] [PubMed] [Google Scholar]
  13. Brennan T. J., Edmondson D. G., Li L., Olson E. N. Transforming growth factor beta represses the actions of myogenin through a mechanism independent of DNA binding. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3822–3826. doi: 10.1073/pnas.88.9.3822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Casini A., Pinzani M., Milani S., Grappone C., Galli G., Jezequel A. M., Schuppan D., Rotella C. M., Surrenti C. Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells. Gastroenterology. 1993 Jul;105(1):245–253. doi: 10.1016/0016-5085(93)90033-9. [DOI] [PubMed] [Google Scholar]
  15. Castilla A., Prieto J., Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 1991 Apr 4;324(14):933–940. doi: 10.1056/NEJM199104043241401. [DOI] [PubMed] [Google Scholar]
  16. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  17. Ellis L., Clauser E., Morgan D. O., Edery M., Roth R. A., Rutter W. J. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell. 1986 Jun 6;45(5):721–732. doi: 10.1016/0092-8674(86)90786-5. [DOI] [PubMed] [Google Scholar]
  18. Fausto N., Mead J. E., Gruppuso P. A., Castilla A., Jakowlew S. B. Effects of TGF-beta s in the liver: cell proliferation and fibrogenesis. Ciba Found Symp. 1991;157:165–177. doi: 10.1002/9780470514061.ch11. [DOI] [PubMed] [Google Scholar]
  19. Feng L., Tang W. W., Loskutoff D. J., Wilson C. B. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol. 1993 May;3(11):1753–1764. doi: 10.1681/ASN.V3111753. [DOI] [PubMed] [Google Scholar]
  20. Friedman S. L., Roll F. J., Boyles J., Bissell D. M. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8681–8685. doi: 10.1073/pnas.82.24.8681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gressner A. M., Bachem M. G. Molecular mechanisms of liver fibrogenesis--a homage to the role of activated fat-storing cells. Digestion. 1995;56(5):335–346. doi: 10.1159/000201257. [DOI] [PubMed] [Google Scholar]
  23. Heino J., Massagué J. Cell adhesion to collagen and decreased myogenic gene expression implicated in the control of myogenesis by transforming growth factor beta. J Biol Chem. 1990 Jun 25;265(18):10181–10184. [PubMed] [Google Scholar]
  24. Hemsley A., Arnheim N., Toney M. D., Cortopassi G., Galas D. J. A simple method for site-directed mutagenesis using the polymerase chain reaction. Nucleic Acids Res. 1989 Aug 25;17(16):6545–6551. doi: 10.1093/nar/17.16.6545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ignotz R. A., Massagué J. Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8530–8534. doi: 10.1073/pnas.82.24.8530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ikeda T., Lioubin M. N., Marquardt H. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry. 1987 May 5;26(9):2406–2410. doi: 10.1021/bi00383a002. [DOI] [PubMed] [Google Scholar]
  27. Jirtle R. L., Meyer S. A. Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression. Dig Dis Sci. 1991 May;36(5):659–668. doi: 10.1007/BF01297035. [DOI] [PubMed] [Google Scholar]
  28. Kagami S., Border W. A., Miller D. E., Noble N. A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994 Jun;93(6):2431–2437. doi: 10.1172/JCI117251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ketteler M., Noble N. A., Border W. A. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol. 1995;57:279–295. doi: 10.1146/annurev.ph.57.030195.001431. [DOI] [PubMed] [Google Scholar]
  30. Kingsley D. M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994 Jan;8(2):133–146. doi: 10.1101/gad.8.2.133. [DOI] [PubMed] [Google Scholar]
  31. Kopp J. B., Factor V. M., Mozes M., Nagy P., Sanderson N., Böttinger E. P., Klotman P. E., Thorgeirsson S. S. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest. 1996 Jun;74(6):991–1003. [PubMed] [Google Scholar]
  32. Kozak L. P., Kozak U. C., Clarke G. T. Abnormal brown and white fat development in transgenic mice overexpressing glycerol 3-phosphate dehydrogenase. Genes Dev. 1991 Dec;5(12A):2256–2264. doi: 10.1101/gad.5.12a.2256. [DOI] [PubMed] [Google Scholar]
  33. Kulkarni A. B., Huh C. G., Becker D., Geiser A., Lyght M., Flanders K. C., Roberts A. B., Sporn M. B., Ward J. M., Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770–774. doi: 10.1073/pnas.90.2.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem. 1980 Mar 1;102(2):344–352. doi: 10.1016/0003-2697(80)90165-7. [DOI] [PubMed] [Google Scholar]
  35. MacDougald O. A., Lane M. D. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem. 1995;64:345–373. doi: 10.1146/annurev.bi.64.070195.002021. [DOI] [PubMed] [Google Scholar]
  36. Massagué J., Cheifetz S., Endo T., Nadal-Ginard B. Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8206–8210. doi: 10.1073/pnas.83.21.8206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Massagué J., Polyak K. Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev. 1995 Feb;5(1):91–96. doi: 10.1016/s0959-437x(95)90059-4. [DOI] [PubMed] [Google Scholar]
  38. Massagué J. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell. 1996 Jun 28;85(7):947–950. doi: 10.1016/s0092-8674(00)81296-9. [DOI] [PubMed] [Google Scholar]
  39. Nath K. A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992 Jul;20(1):1–17. doi: 10.1016/s0272-6386(12)80312-x. [DOI] [PubMed] [Google Scholar]
  40. Oberhammer F. A., Pavelka M., Sharma S., Tiefenbacher R., Purchio A. F., Bursch W., Schulte-Hermann R. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5408–5412. doi: 10.1073/pnas.89.12.5408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Roberts A. B., Sporn M. B. Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis. Int J Rad Appl Instrum B. 1987;14(4):435–439. doi: 10.1016/0883-2897(87)90020-1. [DOI] [PubMed] [Google Scholar]
  42. Russell W. E., Coffey R. J., Jr, Ouellette A. J., Moses H. L. Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5126–5130. doi: 10.1073/pnas.85.14.5126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A. B., Sporn M. B., Thorgeirsson S. S. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2572–2576. doi: 10.1073/pnas.92.7.2572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Schackert H. K., Fan D., Fidler I. J. Transient inhibition of liver regeneration in mice by transforming growth factor-beta 1 encapsulated in liposomes. Cancer Commun. 1990;2(5):165–171. [PubMed] [Google Scholar]
  45. Short M. K., Clouthier D. E., Schaefer I. M., Hammer R. E., Magnuson M. A., Beale E. G. Tissue-specific, developmental, hormonal, and dietary regulation of rat phosphoenolpyruvate carboxykinase-human growth hormone fusion genes in transgenic mice. Mol Cell Biol. 1992 Mar;12(3):1007–1020. doi: 10.1128/mcb.12.3.1007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel G., Calvin D. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992 Oct 22;359(6397):693–699. doi: 10.1038/359693a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Sparks R. L., Allen B. J., Strauss E. E. TGF-beta blocks early but not late differentiation-specific gene expression and morphologic differentiation of 3T3 T proadipocytes. J Cell Physiol. 1992 Mar;150(3):568–577. doi: 10.1002/jcp.1041500318. [DOI] [PubMed] [Google Scholar]
  48. Sparks R. L., Scott R. E. Transforming growth factor type beta is a specific inhibitor of 3T3 T mesenchymal stem cell differentiation. Exp Cell Res. 1986 Aug;165(2):345–352. doi: 10.1016/0014-4827(86)90588-4. [DOI] [PubMed] [Google Scholar]
  49. Spiegelman B. M., Ginty C. A. Fibronectin modulation of cell shape and lipogenic gene expression in 3T3-adipocytes. Cell. 1983 Dec;35(3 Pt 2):657–666. doi: 10.1016/0092-8674(83)90098-3. [DOI] [PubMed] [Google Scholar]
  50. Taurog J. D., Maika S. D., Simmons W. A., Breban M., Hammer R. E. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol. 1993 May 1;150(9):4168–4178. [PubMed] [Google Scholar]
  51. Tomooka S., Border W. A., Marshall B. C., Noble N. A. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 1992 Dec;42(6):1462–1469. doi: 10.1038/ki.1992.442. [DOI] [PubMed] [Google Scholar]
  52. Torti F. M., Torti S. V., Larrick J. W., Ringold G. M. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta. J Cell Biol. 1989 Mar;108(3):1105–1113. doi: 10.1083/jcb.108.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Vaidya T. B., Rhodes S. J., Taparowsky E. J., Konieczny S. F. Fibroblast growth factor and transforming growth factor beta repress transcription of the myogenic regulatory gene MyoD1. Mol Cell Biol. 1989 Aug;9(8):3576–3579. doi: 10.1128/mcb.9.8.3576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Walton G., Buttyan R., Garcia-Montes E., Olsson C. A., Hensle T. W., Sawczuk I. S. Renal growth factor expression during the early phase of experimental hydronephrosis. J Urol. 1992 Aug;148(2 Pt 2):510–514. doi: 10.1016/s0022-5347(17)36641-7. [DOI] [PubMed] [Google Scholar]
  55. Wrana J. L., Attisano L. MAD-related proteins in TGF-beta signalling. Trends Genet. 1996 Dec;12(12):493–496. doi: 10.1016/s0168-9525(96)30109-1. [DOI] [PubMed] [Google Scholar]
  56. Wu H., Wade M., Krall L., Grisham J., Xiong Y., Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev. 1996 Feb 1;10(3):245–260. doi: 10.1101/gad.10.3.245. [DOI] [PubMed] [Google Scholar]
  57. Yeh W. C., McKnight S. L. Regulation of adipose maturation and energy homeostasis. Curr Opin Cell Biol. 1995 Dec;7(6):885–890. doi: 10.1016/0955-0674(95)80074-3. [DOI] [PubMed] [Google Scholar]
  58. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J. M. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994 Dec 1;372(6505):425–432. doi: 10.1038/372425a0. [DOI] [PubMed] [Google Scholar]
  59. Zimmer D. B., Magnuson M. A. Immunohistochemical localization of phosphoenolpyruvate carboxykinase in adult and developing mouse tissues. J Histochem Cytochem. 1990 Feb;38(2):171–178. doi: 10.1177/38.2.1688895. [DOI] [PubMed] [Google Scholar]
  60. ten Dijke P., Miyazono K., Heldin C. H. Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol. 1996 Apr;8(2):139–145. doi: 10.1016/s0955-0674(96)80058-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES